|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.650 USD | +5.44% |
|
+8.39% | +50.97% |
| Market Cap | 81.54M 70.28M 64.71M 60.76M 114M 7.71B 115M 765M 298M 3.78B 306M 300M 13.08B | P/E Ratio 2026 * |
-0.21x | P/E Ratio 2027 * | -0.21x |
|---|---|---|---|---|---|
| Enterprise Value | 36.36M 31.33M 28.85M 27.09M 50.86M 3.44B 51.4M 341M 133M 1.68B 136M 134M 5.83B | EV / Sales 2026 * |
10.6x | EV / Sales 2027 * | 25.4x |
| Free-Float |
-
| Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Limited
| 1 day | +5.44% | ||
| 1 week | +8.39% | ||
| Current month | +12.86% | ||
| 1 month | +15.38% | ||
| 3 months | +28.81% | ||
| 6 months | +51.47% | ||
| Current year | +50.97% |
| 1 week | 3.98 |  | 4.7 |
| 1 month | 3.88 | | 5.04 |
| Current year | 3.02 | | 5.25 |
| 1 year | 2.66 | | 7 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 27.5 |
| 10 years | 1 | | 66.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 2021-01-06 |
Abby Niven
DFI | Director of Finance/CFO | - | 2024-09-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 2005-07-28 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 2011-08-07 |
David Stamler
BRD | Director/Board Member | 65 | 2025-11-20 |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.42M 2.95M 2.72M 2.55M 4.79M 324M 4.84M 32.11M 12.51M 159M 12.85M 12.58M 549M | 1.6M 1.38M 1.27M 1.19M 2.24M 151M 2.26M 15.01M 5.85M 74.09M 6.01M 5.88M 257M |
| Net income | -13.44M -11.58M -10.67M -10.02M -18.8M -1.27B -19M -126M -49.11M -622M -50.45M -49.38M -2.16B | -22.29M -19.21M -17.69M -16.61M -31.18M -2.11B -31.51M -209M -81.43M -1.03B -83.65M -81.87M -3.58B |
| Net Debt | -45.19M -38.94M -35.86M -33.67M -63.22M -4.27B -63.88M -424M -165M -2.09B -170M -166M -7.25B | -40.88M -35.23M -32.44M -30.46M -57.19M -3.87B -57.79M -383M -149M -1.89B -153M -150M -6.56B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-16 | 4.650 $ | +5.44% | 39,654 |
| 26-06-15 | 4.410 $ | +4.75% | 7,635 |
| 26-06-12 | 4.210 $ | +2.43% | 55,576 |
| 26-06-11 | 4.110 $ | -0.96% | 33,574 |
| 26-06-10 | 4.150 $ | -3.26% | 23,883 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
